Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent

D. R. Session; K. R. Kalli; I. S. Tummon; M. A. Damario; D. A. Dumesic

doi:10.1080/09513590312331290298

Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent

D. R. Session, K. R. Kalli, I. S. Tummon, M. A. Damario, D. A. Dumesic

Obstetrics, Gynecology and Women's Health - Reproductive Endocrinology and Infertility

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. This case report describes the treatment of a patient with atypical endometrial hyperplasia with an insulin-sensitizing agent. A 37-year-old patient presented after failed treatment of endometrial hyperplasia with progestogen therapy. One month after initiating metformin therapy the patient's endometrial biopsy demonstrated proliferative endometrium. This patient's atypical endometrial hyperplasia regressed after the initiation of treatment with an insulin-sensitizing agent. This relatively new class of drugs may provide an adjunct to the therapy of endometrial hyperplasia.

Original language	English (US)
Pages (from-to)	405-407
Number of pages	3
Journal	Gynecological Endocrinology
Volume	17
Issue number	5
DOIs	https://doi.org/10.1080/09513590312331290298
State	Published - Oct 2003

Keywords

Endometrium
Hyperplasia
Insulin
Metformin
Progestogen

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1080/09513590312331290298

OpenUrl availability

Full text

Cite this

@article{82dc26d6f5bb4f16b11cbe251d8abd1b,

title = "Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent",

abstract = "Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. This case report describes the treatment of a patient with atypical endometrial hyperplasia with an insulin-sensitizing agent. A 37-year-old patient presented after failed treatment of endometrial hyperplasia with progestogen therapy. One month after initiating metformin therapy the patient's endometrial biopsy demonstrated proliferative endometrium. This patient's atypical endometrial hyperplasia regressed after the initiation of treatment with an insulin-sensitizing agent. This relatively new class of drugs may provide an adjunct to the therapy of endometrial hyperplasia.",

keywords = "Endometrium, Hyperplasia, Insulin, Metformin, Progestogen",

author = "Session, {D. R.} and Kalli, {K. R.} and Tummon, {I. S.} and Damario, {M. A.} and Dumesic, {D. A.}",

year = "2003",

month = oct,

doi = "10.1080/09513590312331290298",

language = "English (US)",

volume = "17",

pages = "405--407",

journal = "Gynecological Endocrinology",

issn = "0951-3590",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent

AU - Session, D. R.

AU - Kalli, K. R.

AU - Tummon, I. S.

AU - Damario, M. A.

AU - Dumesic, D. A.

PY - 2003/10

Y1 - 2003/10

N2 - Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. This case report describes the treatment of a patient with atypical endometrial hyperplasia with an insulin-sensitizing agent. A 37-year-old patient presented after failed treatment of endometrial hyperplasia with progestogen therapy. One month after initiating metformin therapy the patient's endometrial biopsy demonstrated proliferative endometrium. This patient's atypical endometrial hyperplasia regressed after the initiation of treatment with an insulin-sensitizing agent. This relatively new class of drugs may provide an adjunct to the therapy of endometrial hyperplasia.

AB - Endometrial cancer and hyperplasia have long been associated with diabetes. Hyperinsulinemia may have a direct mitogenic effect on the endometrium and may inhibit the effect of progestogen therapy. This case report describes the treatment of a patient with atypical endometrial hyperplasia with an insulin-sensitizing agent. A 37-year-old patient presented after failed treatment of endometrial hyperplasia with progestogen therapy. One month after initiating metformin therapy the patient's endometrial biopsy demonstrated proliferative endometrium. This patient's atypical endometrial hyperplasia regressed after the initiation of treatment with an insulin-sensitizing agent. This relatively new class of drugs may provide an adjunct to the therapy of endometrial hyperplasia.

KW - Endometrium

KW - Hyperplasia

KW - Insulin

KW - Metformin

KW - Progestogen

UR - http://www.scopus.com/inward/record.url?scp=0242333246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242333246&partnerID=8YFLogxK

U2 - 10.1080/09513590312331290298

DO - 10.1080/09513590312331290298

M3 - Article

C2 - 14710588

AN - SCOPUS:0242333246

SN - 0951-3590

VL - 17

SP - 405

EP - 407

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

IS - 5

ER -

Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this